As the U.S. Congress accelerates regulatory easing for biosimilars, it is expected that the pace of local market entry for K-bio companies will increase and they will benefit as a result.


U.S. Congress Accelerates Biosimilar Regulatory Easing... "K-Bio Companies Expected to Benefit" View original image

According to the industry on June 15, the U.S. Senate Health, Education, Labor, and Pensions Committee will review three major bills related to the Food and Drug Administration (FDA) on June 17, including the Biosimilar Red Tape Reduction Act (S.1954). The key provision of this bill is to amend Section 351(k) of the Public Health Service Act (PHSA) to recognize all approved biopharmaceuticals as biosimilars and to immediately grant them interchangeability with the original reference products.


The U.S. Congress has been moving to eliminate the legal basis for the "interchangeable" biosimilar system, which is unique to the U.S. Previously, even after obtaining biosimilar approval, a separate interchangeability status from the FDA was required for pharmacies to substitute the original drug with a biosimilar. However, if this bill passes, the need for a separate FDA interchangeability assessment will be removed.


A bill with identical content, the Biosimilar Red Tape Reduction Act (H.R.5526), was introduced in the House of Representatives on September 19 last year. Starting with this week's committee review, progress is expected toward the bill's passage, and there are not expected to be significant obstacles in the Senate or House. Once enacted, the Secretary of Health and Human Services will be required to issue, update, and revise the final guidance on the review and approval of biosimilar products within 18 months.



This regulatory easing is expected to provide substantial cost-saving opportunities for domestic companies targeting the U.S. market, such as Celltrion and Samsung Bioepis. The additional crossover clinical trials previously required to obtain interchangeable status will no longer be necessary, saving on clinical trial costs. Furthermore, the market entry timeline for new biosimilar pipelines will be shortened. It is also anticipated that the business environment will improve, as pharmacists in the field will be able to substitute original drugs with company products without separate intervention.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing